Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines

References

• Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: From molecular pathology to targeted treatment. Annu Rev Pathol 2014; 9:1-25; PMID:23937436; https://doi.org/10.1146/annurev-pathol-011110-130324
   PubMed Web of Science ®Google Scholar
• Inda M-D-M, Bonavia R, Seoane J. Glioblastoma multiforme: A look inside its heterogeneous nature. Cancers (Basel) 2014; 6(1):226-39; PMID:24473088; https://doi.org/10.3390/cancers6010226
   PubMed Web of Science ®Google Scholar
• Karsy M, Gelbman M, Shah P, Balumbu O, Moy F, Arslan E. Established and emerging variants of glioblastoma multiforme: Review of morphological and molecular features. Folia Neuropathol 2012; 50(4):301-21; PMID:23319187; https://doi.org/10.5114/fn.2012.32361
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. J Clin Oncol 2013; 31(32):4085-91; PMID:24101040; https://doi.org/10.1200/JCO.2013.49.6968
   PubMed Web of Science ®Google Scholar
• Nanegrungsunk D, Onchan W, Chattipakorn N, Chattipakorn SC. Current evidence of temozolomide and bevacizumab in treatment of gliomas. Neurol Res 2015; 37(2):167-83; PMID:25033940; https://doi.org/10.1179/1743132814Y.0000000423
   PubMed Web of Science ®Google Scholar
• Cuddapah VA, Robel S, Watkins S, Sontheimer H. A neurocentric perspective on glioma invasion. Nat Rev Neurosci 2014; 15(7):455-65; PMID:24946761; https://doi.org/10.1038/nrn3765
   PubMed Web of Science ®Google Scholar
• Harris AL. Hypoxia — A key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2(1):38-47; PMID:11902584; https://doi.org/10.1038/nrc704
   PubMed Web of Science ®Google Scholar
• Vaupel P, Höckel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 2007; 9(8):1221-35; PMID:17536958; https://doi.org/10.1089/ars.2007.1628
   PubMed Web of Science ®Google Scholar
• Combs SE, Schmid TE, Vaupel P, Multhoff G. Stress response leading to resistance in glioblastoma- The need for innovative radiotherapy (iRT) concepts. Cancers (Basel) 2016; 8(1):15; PMID:26771644; https://doi.org/10.3390/cancers8010015
   PubMed Web of Science ®Google Scholar
• Li P, Zhou C, Xu L, Xiao H. Hypoxia enhances stemness of cancer stem cells in glioblastoma: An in vitro study. Int J Med Sci 2013; 10(4):399-407; PMID:23471193; https://doi.org/10.7150/ijms.5407 10.7150/ijms.5770 10.7150/ijms.5224
   PubMed Web of Science ®Google Scholar
• Joseph J V, Conroy S, Pavlov K, Sontakke P, Tomar T, Eggens-Meijer E, Balasubramaniyan V, Wagemakers M, den Dunnen WF, Kruyt FA. Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIFα -ZEB1 axis. Cancer Lett 2015; 359(1):107-16; PMID:25592037; https://doi.org/10.1016/j.canlet.2015.01.010
   PubMed Web of Science ®Google Scholar
• Matschke J, Riffkin H, Klein D, Handrick R, Lüdemann L, Metzen E, Shlomi T, Stuschke M, Jendrossek V. Targeted inhibition of glutamine-dependent glutathione metabolism overcomes death resistance induced by chronic cycling hypoxia. Antioxid Redox Signal 2016; 25(2):89-107; PMID:27021152; https://doi.org/10.1089/ars.2015.6589
   PubMed Web of Science ®Google Scholar
• Dokic I, Hartmann C, Herold-Mende C, Régnier-Vigouroux A. Glutathione peroxidase 1 activity dictates the sensitivity of glioblastoma cells to oxidative stress. Glia 2012; 60(11):1785-800; PMID:22951908; https://doi.org/10.1002/glia.22397
   PubMed Web of Science ®Google Scholar
• Kanzawa T, Bedwell J, Kondo Y, Kondo S, Germano IM. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 2003; 99(6):1047-52; PMID:14705733; https://doi.org/10.3171/jns.2003.99.6.1047
   PubMed Web of Science ®Google Scholar
• Jiang G, Li L-T, Xin Y, Zhang L, Liu Y-Q, Zheng J-N. Strategies to improve the killing of tumors using temozolomide: Targeting the DNA repair protein MGMT. Curr Med Chem 2012; 19(23):3886-92; PMID:22788764; https://doi.org/10.2174/092986712802002446
   PubMed Web of Science ®Google Scholar
• van Nifterik KA, van den Berg J, van der Meide WF, Ameziane N, Wedekind LE, Steenbergen RDM, Leenstra S, Lafleur MV, Slotman BJ, Stalpers LJ, et al. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer 2010; 103(1):29-35; PMID:20517307; https://doi.org/10.1038/sj.bjc.6605712
   PubMed Web of Science ®Google Scholar
• Karsy M, Neil JA, Guan J, Mark MA, Colman H, Jensen RL. A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus 2015; 38(3):1-8; PMID:25727226; https://doi.org/10.3171/2015.1.FOCUS14755
   PubMed Web of Science ®Google Scholar
• Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH. Emerging immunotherapies for glioblastoma. Expert Opin Emerg Drugs 2016; 21(2):133-45; PMID:27223671; https://doi.org/10.1080/14728214.2016.1186643
   PubMed Web of Science ®Google Scholar
• Bien-möller S, Lange S, Holm T, Böhm A, Paland H, Küpper J, Herzog S, Weitmann K, Havemann C, Vogelgesang S, et al. Expression of S1P metabolizing enzymes and receptors correlate with survival time and regulate cell migration in glioblastoma multiforme. Oncotarget 2016; 7(11):13031-46; PMID:26887055; https://doi.org/10.18632/oncotarget.7366
   PubMed Web of Science ®Google Scholar
• Abuhusain HJ, Matin A, Qiao Q, Shen H, Kain N, Day BW, Stringer BW, Daniels B, Laaksonen MA, Teo C, et al. A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis. J Biol Chem 2013; 288(52):37355-64; PMID:24265321; https://doi.org/10.1074/jbc.M113.494740
   PubMed Web of Science ®Google Scholar
• Liu H, Chakravarty D, Maceyka M, Milstien S, Spiegel S. Sphingosine kinases: A novel family of lipid kinases. Prog Nucleic Acid Res Mol Biol 2002; 71:493-506; PMID:12102559; https://doi.org/10.1016/S0079-6603(02)71049-0
   PubMed Web of Science ®Google Scholar
• Strub GM, Maceyka M, Hait NC, Milstien S, Spiegel S. Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol 2010; 688:141-55; PMID:20919652; https://doi.org/10.1007/978-1-4419-6741-1_10
   PubMed Web of Science ®Google Scholar
• Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: An autocrine and paracrine network. Nat Rev Immunol 2005;5(7):560-70; PMID:15999095; https://doi.org/10.1038/nri1650
   PubMed Web of Science ®Google Scholar
• Quint K, Stiel N, Neureiter D, Schlicker HU, Nimsky C, Ocker M, Strik H, Kolodziej MA. The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas. Tumor Biol 2014; 35(9):8979-89; PMID:24903384; https://doi.org/10.1007/s13277-014-2172-x
   PubMed Web of Science ®Google Scholar
• Anelli V, Gault CR, Cheng AB, Obeid LM. Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells: Role of hypoxia-inducible factors 1 and 2. J Biol Chem 2008; 283(6):3365-75; PMID:18055454; https://doi.org/10.1074/jbc.M708241200
   PubMed Web of Science ®Google Scholar
• Riccitelli E, Giussani P, Di Vito C, Condomitti G, Tringali C, Caroli M, Galli R, Viani P, Riboni L. Extracellular sphingosine-1-phosphate: A novel actor in human glioblastoma stem cell survival. PLoS One 2013; 8(6):1-11; PMID:23826381; https://doi.org/10.1371/journal.pone.0068229
   PubMed Web of Science ®Google Scholar
• Kunkel GT, Maceyka M, Milstien S, Spiegel S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov 2013; 12(9):688-702; PMID:23954895; https://doi.org/10.1038/nrd4099
   PubMed Web of Science ®Google Scholar
• Canals D, Hannun YA. Novel chemotherapeutic drugs in sphingolipid cancer research. Handb Exp Pharmacol 2013; (215):211-38; PMID:23579458; https://doi.org/10.1007/978-3-7091-1368-4_12
   PubMedGoogle Scholar
• Mora R, Dokic I, Kees T, Hüber CM, Keitel D, Geibig R, Brügge B, Zentgraf H, Brady NR, Régnier-Vigouroux A. Sphingolipid rheostat alterations related to transformation can be exploited for specific induction of lysosomal cell death in murine and human glioma. Glia 2010; 58(11):1364-83; PMID:20607862; https://doi.org/10.1002/glia.21013
   PubMed Web of Science ®Google Scholar
• Gault CR, Obeid LM. Still benched on its way to the bedside: Sphingosine kinase 1 as an emerging target in cancer chemotherapy. Crit Rev Biochem Mol Biol 2011; 46(4):342-51; PMID:21787121; https://doi.org/10.3109/10409238.2011.597737
   PubMed Web of Science ®Google Scholar
• Huwiler A, Kotelevets N, Xin C, Pastukhov O, Pfeilschifter J, Zangemeister-Wittke U. Loss of sphingosine kinase-1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicin-induced DNA damage. Br J Pharmacol 2011; 162(2):532-43; PMID:20883472; https://doi.org/10.1111/j.1476-5381.2010.01053.x
   PubMed Web of Science ®Google Scholar
• French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63:5962-9; PMID:14522923
   PubMed Web of Science ®Google Scholar
• Noack J, Choi J, Richter K, Kopp-Schneider A, Régnier-Vigouroux A. A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy. Cell Death Dis 2014; 5:e1425; PMID:25255218; https://doi.org/10.1038/cddis.2014.384
   PubMed Web of Science ®Google Scholar
• Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1(5):2315-9; PMID:17406473; https://doi.org/10.1038/nprot.2006.339
   PubMed Web of Science ®Google Scholar
• Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 2003; 60:6-20; PMID:12613655; https://doi.org/10.1007/s000180300001
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 10(352):987-96; PMID:15758009; https://doi.org/10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar
• Diaz-Miqueli A, Saurez Martinez G. Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: Challenges and opportunities. OncoTarget Ther 2013; 6:931-42; PMID:23926436; https://doi.org/10.2147/OTT.S33532
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370(8):709-22; PMID:24552318; https://doi.org/10.1056/NEJMoa1308345
   PubMed Web of Science ®Google Scholar
• Masood R, Roy I, Zu S, Hochstim C, Yong K-T, Law W-C, Ding H, Sinha UK, Prasad PN. Gold nanorod-sphingosine kinase siRNA nanocomplexes: A novel therapeutic tool for potent radiosensitization of head and neck cancer. Integr Biol (Camb) 2012; 4(2):132-41; PMID:22159374; https://doi.org/10.1039/C1IB00060H
   PubMed Web of Science ®Google Scholar
• Pchejetski D, Böhler T, Stebbing J, Waxman J. Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. Nat Rev Urol 2011; 8(10):569-678; PMID:21912422; https://doi.org/10.1038/nrurol.2011.117
   PubMed Web of Science ®Google Scholar
• Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH, Lin YF, Shih CM. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med 2012; 52:377-91; PMID:22094224; https://doi.org/10.1016/j.freeradbiomed.2012.02.028 10.1016/j.freeradbiomed.2011.10.487
   PubMed Web of Science ®Google Scholar
• Erasimus H, Gobin M, Niclou S, Van Dyck E. DNA repair mechanisms and their clinical impact in glioblastoma. Mutat Res Mutat Res 2016; 769:19-35; PMID:27543314; https://doi.org/10.1016/j.mrrev.2016.05.005
   PubMed Web of Science ®Google Scholar
• Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, Weber KJ. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′ deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 1998; 41(4):875-82; PMID:9652852; https://doi.org/10.1016/S0360-3016(98)00105-9
   PubMed Web of Science ®Google Scholar